766 results on '"Bashey, Asad"'
Search Results
2. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
3. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation
4. Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)
5. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
6. Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
7. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
8. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
9. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
10. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
11. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
12. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
13. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
14. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation
15. Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
16. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
17. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
18. Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant
19. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
20. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
21. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
22. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
23. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Acute Kidney Injury Requiring Dialysis (AKI-D) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT): Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study
24. HLA-DQ G1/G2 Heterodimer Genotype Impacts Relapse and Survival Following Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
25. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial
26. Incidence of Mucositis and Effect on Outcomes with Myeloablative/Dose-Intensified Conditioning Regimens for HLA-Haploidentical Allotransplantation
27. Impact of Acute and Chronic Graft-Versus-Host Disease (GVHD) on Non-Relapse Mortality and Survival Following Haploidentical Donor Transplantation.
28. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
29. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation
30. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
31. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.
32. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
33. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors
34. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide
35. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation
36. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
37. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant
38. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)
39. Survival following allogeneic transplant in patients with myelofibrosis
40. Ipilimumab for Patients with Relapse after Allogeneic Transplantation
41. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study
42. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
43. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy
44. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
45. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
46. Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program
47. Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes
48. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis
49. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
50. AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.